Related Experiment Video
Updated: Feb 10, 2026

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
Effect of Antihypertensive Medication on Cerebral Small Vessel Disease: A Systematic Review and Meta-Analysis
Tessa van Middelaar1,2, Tanja E Argillander3, Floris H B M Schreuder4
1From the Department of Neurology, Donders Institute for Brain, Cognition, and Behavior (T.v.M., F.H.B.M.S., E.R., C.J.M.K.) t.vanmiddelaar@amc.uva.nl.
Insights
Antihypertensive medication (AHM) slows white matter hyperintensity progression in cerebral small vessel disease. However, AHM showed no effect on brain atrophy, and data on other markers are lacking.
Area of Science:
- Neurology
- Cardiology
- Radiology
Background:
- Hypertension is a significant risk factor for cerebral small vessel disease (CSVD).
- Understanding the impact of antihypertensive medication (AHM) on CSVD progression is crucial.
Purpose of the Study:
- To systematically evaluate the effect of antihypertensive medication (AHM) on the progression of cerebral small vessel disease (CSVD) markers.
- To synthesize evidence from randomized controlled trials (RCTs) investigating AHM's impact on key CSVD indicators.
Main Methods:
- A systematic literature search was conducted across electronic databases up to January 30, 2017.
- A random-effects meta-analysis was performed on data from 4 RCTs, focusing on MRI-assessed CSVD markers over at least one year.
- Standardized mean difference was used to quantify treatment effects.
Main Results:
- Antihypertensive medication (AHM) demonstrated a significant protective effect, reducing white matter hyperintensity progression over 28–47 months (SMD -0.19; 95% CI -0.32 to -0.06).
- Two trials reported conflicting results regarding AHM's effect on brain atrophy progression.
- No trials reported on the impact of AHM on lacunes, microbleeds, enlarged perivascular spaces, or acute small subcortical infarcts.
Conclusions:
- Antihypertensive medication (AHM) offers a protective effect against the progression of white matter hyperintensities in patients with cerebral small vessel disease.
- Current evidence does not support an effect of AHM on brain atrophy progression.
- Further research is needed to investigate the effects of AHM on other CSVD markers, as trials are currently lacking.
Background And Purpose:
Hypertension is an important risk factor for cerebral small vessel disease. We aimed to study the effect of antihypertensive medication (AHM) on the progression of cerebral small vessel disease.
Methods:
We performed a systematic literature search of electronic databases up to January 30, 2017, for randomized controlled trials on the effect of AHM on ≥1 cerebral small vessel disease magnetic resonance imaging markers (ie, white matter hyperintensities, lacunes, microbleeds, enlarged perivascular spaces, acute small subcortical infarcts, and brain atrophy) after ≥1 year. We performed a random-effects meta-analysis using standardized mean difference.
Results:
We included 4 trials, including patients with stroke, with diabetes mellitus, and people ≥70 years of age. Patients in the AHM group had less progression of white matter hyperintensity during 28 to 47 months (standardized mean difference, -0.19; 95% confidence interval, -0.32 to -0.06; I2=20%; n=1369). Two trials reported on progression of brain atrophy with conflicting results. None of the trials reported on other cerebral small vessel disease markers.
Conclusions:
AHM has a protective effect on the progression of white matter hyperintensities, but no effect on brain atrophy. There are no trials on the effect of AHM on lacunes, microbleeds, enlarged perivascular spaces, or acute small subcortical infarcts.
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Antihypertensive Drugs: Vasodilators
Random and Systematic Errors
Directing Effect of Substituents: meta-Directing Groups

